ERYTECH Pharma S.A. (ERYP) |
|
0.591 0.041 (7.45%)
|
01-27 16:00 |
|
Open: |
0.59 |
Pre. Close: |
0.55 |
|
High:
|
0.641 |
Low:
|
0.52 |
|
Volume:
|
38,317 |
Market Cap:
|
21(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:44:13 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.76 One year: 0.89 |
| Support: |
Support1: 0.43 Support2: 0.3 |
| Resistance: |
Resistance1: 0.65 Resistance2: 0.76 |
| Pivot: |
0.52  |
| Moving Average: |
MA(5): 0.55  MA(20): 0.47
MA(100): 0.59 MA(250): 1.03 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 71.6 %D(3): 67.5 |
| RSI: |
RSI(14): 61 |
| 52-week: |
High: 2.18 Low: 0.3 |
| Average Vol(K): |
3-Month: 40 (K) 10-Days: 26 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ERYP ] has closed below upper band by 22.7%. Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.64 - 0.64 |
0.64 - 0.65 |
|
Low:
|
0.51 - 0.52 |
0.52 - 0.52 |
|
Close:
|
0.59 - 0.59 |
0.59 - 0.6 |
|
Company Description |
|
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France. |
Headline News |
Fri, 27 Jan 2023
European Equities Move Lower Friday, Set to End Week in Negative Territory - Marketscreener.com
Tue, 24 Jan 2023
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are ... - Investing.com UK
Wed, 18 Jan 2023
Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading - Marketscreener.com
Wed, 11 Jan 2023
Erytech Pharma SA (ERYP) Stock Has Risen 38.89% This Week: Buy, Hold, or Sell? - InvestorsObserver
Wed, 12 Oct 2022
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 ... - Markets Insider
Mon, 12 Sep 2022
ERYTECH Provides Business and Financial Update for the First Half ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
31 (M) |
|
% Held by Insiders
|
2.826e+007 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
46 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.932e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
943.2 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
2.2e+006 |
|
Gross Profit (p.s.)
|
-37.5 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
2.67949e+006 |
|
Qtrly Earnings Growth
|
-1.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
1.28 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
43220 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
